Next Phase Newsletter

A venture capital firm located in New York City focuses on the life science industrials and invests in companies that develop tools, technologies, and services for discovery, development, and manufacturing of biologics and related therapies. The firm is focused on early-stage venture and growth equity investments. Typical equity investments range from $500k-$5 million. The firm has $65M AUM, 7 active portfolio companies to date, and is open to either leading or co-leading in a financing round.

Within life sciences, the firm is specifically focused on life science industrials: the tools, technologies, and services that enable the discovery, development, and manufacturing of life-saving therapies. The firm does not invest in therapeutics or medical devices. The firm considers Seed to Series B stage

The firm with entrepreneurs and their teams to overcome inflection points in growth. The firm takes a hands-on approach to work with its portfolio companies through focused operational and commercial guidance and an engaged approach to supporting entrepreneurial ventures.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded 2013, a venture capital firm is headquartered in San Francisco. The firm is investing from its most recent fund, which closed in early 2020 at $50 M. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A Toronto based venture capital firm founded in 2016 is investing out of its second fund, which was initially closed in October 2020 at USD 150 million. Among the 150 million, the firm manages to invest 100 million directly in companies while the other 50 million will invest in funds. The firm focuses on investments in three main sectors: Biopharmaceutical, Healthcare Platform & Services, and Technology (i.e., SAAS, Fintech). The firm provides initial investments at USD 3-5 million, and it will also reserve a further amount for follow-on financing and supports the startups in strategic partnerships. The firm is interested in pre-clinical to clinical-stage biotech companies. The firm invests primarily in North America but also opens to invest in Europe or China.

The firm is looking for new opportunities in the life science space, including therapeutics, diagnostics, and healthcare platforms. The firm’s investments to date have included companies developing in cell therapy, oncology, neuroscience, and drug-discovery platform. The firm is opportunistic in terms of sector, subsectors, and indications. The firm will also consider orphan drugs. Within medical devices and digital health, the firm will only consider companies that already have a USD 10 million minimum revenue. The firm will only co-invest and will prefer to co-invest with well-known lead investors.

The firm does not have specific requirements on companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The healthcare system operates 80+ hospitals across Asia, the Middle East and Turkey. The firm has an innovation office that acts as a corporate VC arm, which has committed capital of $80 million to invest in the digital health space. The firm typically invests $5-10 million per opportunity, and will invest in companies worldwide that are interested in expanding into Asia.

The fund only invests in the digital health space. The firm is interested in many areas of digital health, diagnostics, and tech-enabled healthcare services, including wellness, digital therapeutics, AI, healthcare data, remote monitoring, chronic disease management, etc. The firm does not invest in biopharma or medtech.

The firm will invest globally, and is focused on startups that are interested in expanding into Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm was founded in 1999 and has offices in the Southeast and Midwest US. The firm has three funds under management. The fund typically makes investments of $2-5 million, and also considers participating in larger syndicated rounds. The firm considers minority and control equity positions as well as subordinated debt. The firm invests throughout the USA. The firm prefers to lead or co-lead investment rounds.

The firm is focused on products or services within the health and wellness space. In addition to wellness-oriented products and services, the firm is also interested in opportunities in the digital health, medical technology, healthcare IT, healthcare services, and biotech lab equipment sectors. The fund’s previous life science investments include surgical devices and instrumentation.

The firm invests in second-stage companies approaching $5 million in revenue. The firm has a focus on companies led by women or which target female consumers, though this is not a requirement for investment. In the medical device sector, the firm only invests in companies with products approved by the FDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, the firm has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. The firm has received three NDA approvals, including two in mainland China and one in Taiwan, and multiple late-stage candidates are in pivotal trials or registrational stages. The firm’s vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. The company is currently seeking in-licensing, out-licensing and partnership opportunities globally.

The firm is particularly interested in first-in-class, truly innovative oncology assets from pre-clinical to market except for CAR-T therapy and gene therapy. The firm is interested in opportunities for both greater China as well as global market.

The firm’s team is flexible and is open to working with all different kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 2011 and based is Dallas, Taxas, the firm is focused on healthcare companies and makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.